18. Beta-Blockade in Septic Shock (Esmolol/Landiolol)

Quick Recap

Cross-cutting protocol — companion to Vasopressor & Inotrope Selection & Titration protocol. Addresses a genuinely counterintuitive proposition — deliberately blocking beta-adrenergic receptors in a patient already requiring vasopressor support for shock — and what may be the most dramatic single-center-to-multicenter evidence reversal in this entire library: a trial reporting an 80.5% vs. 49.4% mortality difference, followed by a multicenter confirmatory trial stopped early specifically for a signal of harm.

1. Definition

Beta-blockade in septic shock: the deliberate administration of a short-acting, cardioselective beta-1 blocker (esmolol or landiolol, both ultra-short-acting agents allowing rapid titration and reversal) to a vasopressor-dependent septic shock patient with persistent tachycardia, aiming to reduce heart rate to a target range (typically 80–94 bpm) — a deliberately counterintuitive intervention given that beta-blockers are not traditionally used in shock states and carry theoretical risk of worsening cardiovascular decompensation through negative inotropic and hypotensive effects.

The proposed rationale: persistent tachycardia in septic shock, driven by sustained endogenous and exogenous catecholamine (vasopressor) exposure, is proposed to increase myocardial oxygen consumption and cardiac workload, potentially contributing to septic cardiomyopathy and worse outcomes — reducing heart rate toward a more physiologic range is theorized to reduce this metabolic demand and improve myocardial efficiency, distinct from simply treating tachycardia as a vital sign to be normalized for its own sake.

2. Pathophysiology

Septic shock produces a state of sustained, often severe beta-adrenergic receptor stimulation from both the endogenous catecholamine surge of critical illness and the exogenous vasopressor (typically norepinephrine) required to maintain perfusion pressure — this combination can drive persistent tachycardia that, per the theoretical rationale, increases myocardial oxygen demand at a time when myocardial oxygen supply may already be compromised by the underlying shock state, potentially worsening septic cardiomyopathy and contributing to a self-perpetuating cycle of cardiac dysfunction.

The genuine, acknowledged uncertainty regarding mechanism: even the original positive trial's own investigators, and independent editorial commentary accompanying it, explicitly acknowledged that "the mechanism by which esmolol might have improved outcomes...is unclear" — the effects of beta-blockade are described as "multifaceted," potentially involving not only cardiac hemodynamic effects but also immunomodulation (a proposed but incompletely characterized additional mechanism) — this protocol treats the underlying biological mechanism as a genuinely open question throughout, not a settled explanation retrofitted to the trial results.

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses a specific, still-experimental adjunctive therapy decision rather than acute stabilization; cross-reference Septic Shock (revised) and Vasopressor & Inotrope Selection & Titration protocols for the underlying shock management framework this decision would sit within if pursued.

Checklist — if beta-blockade for persistent tachycardia in septic shock is being considered:

4. Focused History

• Duration and persistence of tachycardia despite adequate volume resuscitation and vasopressor titration
• Prior beta-blocker therapy (an exclusion criterion across the major trials)
• Underlying cardiac function, specifically screening for pronounced cardiac dysfunction (e.g., cardiac index ≤2.2 with elevated PAOP, per Morelli's exclusion criteria) or significant valvular disease

5. Comprehensive System-wise Examination

• Cardiovascular: heart rate trend despite standard shock management, hemodynamic stability, evidence of adequate perfusion despite persistent tachycardia

POCUS integration: cardiac function assessment relevant to excluding significant baseline cardiac dysfunction that would represent a relative contraindication.

6. Syndrome Identification — Reframed as Evidence-Status Classification

• Persistent tachycardia in septic shock despite adequate resuscitation, single-center-trial-informed enthusiasm: this population and rationale motivated the original, dramatically positive Morelli trial — current, more rigorous evidence has substantially undermined confidence in this approach (Section 11)
• Any patient being considered for beta-blockade in septic shock outside a formal trial: current evidence status does not support this as routine or even experimental clinical practice given STRESS-L's harm signal, and this protocol does not recommend pursuing this intervention in standard clinical care

7. Differential Diagnosis — Not Applicable

Cross-reference Septic Shock (revised) protocol for the underlying differential of persistent shock/tachycardia; standard causes of inadequately controlled tachycardia (undertreated pain, inadequate sedation, ongoing hypovolemia, occult bleeding) should be actively excluded before attributing persistent tachycardia to a presumed beta-adrenergic-hyperactivity state warranting deliberate blockade.

8. Severity/Risk Assessment — Not a Formal Scoring System

Not applicable in the traditional sense; the relevant "risk assessment" for this protocol is the evidence-status classification in Section 6.

9. Investigations — Not Applicable

10. Point-of-Care Ultrasound — Not a Primary Component

Cardiac function assessment relevant to baseline contraindication screening, as noted in Section 5.

11. Evidence-Based Management — The Full Evidence Arc, From Dramatic Positive Signal to Harm

Morelli (2013) — A Genuinely Extraordinary, Single-Center Result

• Morelli trial (JAMA 2013): a single-center (University of Rome "La Sapienza"), open-label, phase 2 RCT of 154 patients with septic shock and persistent tachycardia (heart rate ≥95 bpm) despite adequate hemodynamic optimization and high-dose norepinephrine — randomized to esmolol titrated to a heart rate target of 80–94 bpm over 96 hours, vs. standard care
• Heart rate control achieved: median reduction of −28 bpm (esmolol) vs. −6 bpm (control), p<0.001 — the drug clearly, reliably achieved its physiological target
• Primary/key clinical result — 28-day mortality: 49.4% (esmolol) vs. 80.5% (control), p<0.001 — an extraordinarily large, statistically robust absolute mortality difference of over 30 percentage points
• Favorable secondary findings: better lactate control, reduced norepinephrine and fluid requirements, higher cardiac stroke volume index, without increased hepatic, renal, or myocardial injury markers compared to control
• Immediate, explicit editorial caution accompanying the original publication: an accompanying JAMA editorial (Pinsky) specifically "cautioned clinicians against applying these results to all patients in septic shock," citing "the limitations of this study and limitations in the current understanding of how beta-blocker therapy can cause such effects" — this caution was present from the very first publication of this dramatic finding, not a retrospective addition after later trials complicated the picture
• The magnitude itself as an immediate, appropriate red flag: independent commentary explicitly noted this was "the first study showing an improvement in cardiac function and 28-day mortality" with beta-blockers in sepsis, while separately discussing "several statistical and methodological limitations that may influence the generalizability of these results" — an 80.5% control-arm mortality rate is itself notably high relative to most contemporary septic shock literature, a pattern worth comparing to the Rumbak tracheostomy outlier discussed in the Early vs. Late Tracheostomy Timing protocol, where an implausibly extreme control-arm event rate should itself prompt scrutiny of population selection or trial conduct rather than being accepted at face value

Meta-Analytic Reinforcement of the Single-Center Signal (2018–2024)

• Multiple meta-analyses pooling Morelli alongside a small number of smaller esmolol trials continued to report a statistically significant pooled mortality benefit for esmolol specifically (e.g., a 2024 meta-analysis reporting RR 0.73, 95% CI 0.57–0.93 for ultrashort-acting beta-blockers broadly, and RR 0.68, 95% CI 0.55–0.84 for esmolol specifically across 5 studies/431 participants) — however, these pooled analyses remained substantially dependent on Morelli's own dramatic single-center result, and did not yet incorporate the large, definitive multicenter trial discussed below, illustrating a genuine, temporarily persisting evidence-synthesis lag

Landi-SEP and J-Land 3S — Earlier Signals of Trouble with the Related Agent Landiolol

• Landi-SEP trial: a multicenter RCT (20 sites, 7 European countries, n=200) testing landiolol (a related, highly selective ultra-short-acting beta-1 blocker) for heart rate control in septic shock with persistent tachycardia — the trial ran with early termination, an early signal that the multicenter replication of this concept was not proceeding as smoothly as the single-center esmolol data had suggested
• J-Land 3S: a separate multicenter trial specifically found that while landiolol did significantly lower heart rate and allowed more patients to reach target range, it did not decrease 28-day mortality
• Meta-analytic pattern specifically distinguishing esmolol from landiolol: pooled analyses have found esmolol associated with a significant mortality benefit signal, while landiolol has shown no significant mortality effect (and a nonsignificant trend toward increased mortality in meta-regression) — raising a genuine, unresolved question about whether any true benefit is agent-specific (esmolol vs. landiolol have different selectivity and pharmacokinetic profiles) or whether the pooled esmolol signal itself remains disproportionately driven by Morelli's single dramatic result rather than representing a broadly replicated, agent-class effect

⚠️ STRESS-L (2023) — The Definitive, Multicenter Trial — Stopped Early for Harm

• STRESS-L trial (Whitehouse et al., JAMA 2023): an open-label, multicenter RCT across 40 UK NHS intensive care units, testing landiolol in adults with septic shock, tachycardia (≥95 bpm), and established norepinephrine dependence for >24 hours — a substantially more rigorous, multicenter design directly motivated by the need to confirm Morelli's single-center finding at scale
• The trial was terminated prematurely on the advice of the independent Data Monitoring Committee, specifically because it was unlikely to demonstrate benefit and because of a signal of possible harm — of a planned 340 participants, only 126 (37%) were enrolled before termination
• Primary outcome (mean SOFA score through 14 days): no significant difference (8.8 landiolol vs. 8.1 standard care, p=0.24) — landiolol did not reduce organ failure
• Secondary outcome — 28-day mortality: 37.1% (landiolol) vs. 25.4% (standard care), an absolute difference of 11.7% trending toward harm (95% CI −4.4% to 27.8%, p=0.16) — not independently statistically significant, but directionally concerning and consistent with the DMC's decision to halt the trial
• 90-day mortality — an even more pronounced, still not quite statistically significant, harm trend: 43.5% (landiolol) vs. 28.6% (standard care), absolute difference 15% (95% CI −1.7% to 31.6%, p=0.08) — a result close to conventional significance, in the opposite direction from Morelli's original dramatic benefit finding
• Consistent physiological signal of harm: landiolol-treated patients had significantly lower mean arterial pressure and significantly higher norepinephrine requirements than standard care — direct, measurable evidence that beta-blockade was compromising hemodynamic stability in this population, precisely the theoretical concern that had made beta-blockade in shock states counterintuitive and controversial from the outset
• A specific, striking, directly-stated observation from the trial's own discussion: "outcomes differed between single-center and multicenter trials, while sensitivity analyses showed the fragility of the primary outcome" — the investigators themselves explicitly framed their result as a cautionary contrast to the single-center literature that preceded it

Practical Synthesis

This represents one of the most dramatic single-center-to-multicenter evidence reversals available in the critical care literature: from a single-center trial reporting a >30 percentage point absolute mortality reduction (49.4% vs. 80.5%), to a multicenter confirmatory trial of a related agent halted early specifically for a signal of possible harm, with both 28-day and 90-day mortality trending in the opposite direction from the original finding, accompanied by direct physiological evidence (lower MAP, higher norepinephrine requirement) of hemodynamic compromise. Current evidence does not support beta-blockade (esmolol or landiolol) for persistent tachycardia in septic shock as routine or even cautiously experimental clinical practice — this should be pursued, if at all, only within a formal, appropriately powered and monitored research protocol, not as an off-protocol adjunctive therapy, however compelling the original single-center physiological rationale and dramatic mortality data may still appear in isolation. The theoretical, mechanistically plausible concern that motivated caution from the very first publication of this concept (Pinsky's 2013 editorial) has now been substantiated by rigorous multicenter trial data, rather than remaining merely a theoretical counterweight to a persuasive single-center result.

12. Organ Support

Directly interacts with Vasopressor & Inotrope Selection & Titration protocol — beta-blockade in this context is fundamentally in tension with, not complementary to, standard vasopressor-based hemodynamic support, and STRESS-L's finding of increased norepinephrine requirement with landiolol directly illustrates this tension in quantified form.

13. Disease-Specific Therapy — Not Currently Recommended

Current evidence does not support a specific dosing or administration recommendation for beta-blockade in septic shock outside a formal research protocol, given STRESS-L's harm signal.

14. Consultation Matrix

15. Monitoring Framework — Not Applicable Outside a Research Context

16. ICU Bundle Checklist

17. Complications

Per STRESS-L's direct findings: reduced mean arterial pressure, increased norepinephrine requirement, and a trend toward increased 28-day and 90-day mortality — real, quantified, physiologically coherent evidence of harm consistent with the theoretical concern that had made this intervention controversial from the outset.

Prevention: avoiding beta-blockade for persistent tachycardia in septic shock outside a formal research context, given current evidence.

18. Escalation & De-escalation — Not Applicable

19. ICU Discharge Criteria — Not Applicable

20. Documentation & Medicolegal Checklist

• If beta-blockade is considered within a research context, explicit documentation of the current evidence status (STRESS-L's harm signal) and research protocol adherence
• Standard causes of persistent tachycardia actively excluded and documented before any consideration of this intervention

21. Key Guidelines

• No major guideline recommends beta-blockade for heart rate control in septic shock as standard practice, consistent with the current evidence status; this remains an area of active research rather than established, guideline-endorsed therapy

22. Landmark Trials

23. Controversies

• This may be the single most dramatic evidence reversal magnitude in this entire library: Morelli's 31-percentage-point absolute mortality difference (49.4% vs. 80.5%) is an extraordinarily large effect size for any critical care intervention — larger than nearly any other single-trial finding discussed across this library's other topics — and STRESS-L's result trended in the directly opposite direction, with physiological evidence (lower MAP, higher norepinephrine requirement) directly supporting a harm mechanism rather than merely failing to replicate a null effect. This protocol treats the sheer magnitude of Morelli's original effect size as itself a red flag that should have prompted more caution before the concept gained the traction it did, consistent with the general principle (echoed elsewhere in this library, e.g., the Vitamin C/Marik protocol's discussion of "biologically implausible" effect sizes) that unusually large single-trial effects warrant particular skepticism pending confirmation.
• Esmolol vs. landiolol — a genuinely unresolved agent-specific question: STRESS-L specifically tested landiolol, not esmolol — meaning it does not, strictly speaking, directly refute Morelli's esmolol-specific finding. However, the theoretical mechanism (beta-1 blockade reducing heart rate and myocardial oxygen demand) should plausibly apply similarly to both highly selective ultra-short-acting beta-1 blockers, and the consistent pattern of multicenter trials (both esmolol-adjacent J-Land 3S and landiolol-specific STRESS-L) failing to replicate Morelli's dramatic effect, culminating in STRESS-L's harm signal, argues against assuming esmolol specifically remains unaffected by this broader pattern of non-replication — though a large, adequately powered, multicenter esmolol-specific trial has not, to date, definitively closed this specific question.
• The persistence of favorable pooled meta-analyses even after STRESS-L's harm signal reflects a genuine, temporary evidence-synthesis lag — meta-analyses published before full incorporation of STRESS-L's data continued to show pooled benefit substantially driven by Morelli's outsized single-center effect; updated syntheses incorporating STRESS-L's harm signal are needed to more accurately reflect the current, more cautious evidence balance, and clinicians encountering older meta-analyses in this space should specifically check whether STRESS-L has been incorporated before weighing their conclusions.
• Why did the single-center and multicenter results diverge so dramatically? As with several other examples throughout this library, plausible explanations include patient population differences (Morelli's single-center Roman ICU population vs. STRESS-L's 40-site UK NHS population), the inherent statistical fragility of dramatic single-center effect sizes, and possibly genuine heterogeneity in how different ICU systems manage the broader septic shock resuscitation context within which beta-blockade would be layered — STRESS-L's own investigators explicitly noted "sensitivity analyses showed the fragility of the primary outcome," a direct, self-critical acknowledgment worth taking seriously.

24. References

1. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683-1691.
2. Pinsky MR. Beta blockade in septic shock: targeting a moving physiologic target [editorial]. JAMA. 2013;310(16):1677-1678.
3. De Backer D, Annane D. Beta-blockers in septic shock to optimize hemodynamics? We are not sure. Crit Care. 2014.
4. Effect of ultrashort-acting β-blockers on 28-day mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a meta-analysis of randomized controlled trials and trial sequential analysis. Front Pharmacol. 2024.
5. Whitehouse T, Hossain A, Perkins GD, et al. Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA. 2023;330(17):1641-1652.
6. Hollenberg SM. Landiolol for septic shock — caution warranted [editorial]. JAMA. 2023;330(17):1627-1628.
7. Gordon AC, et al. Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L study protocol for a randomised trial. BMJ Open. 2020.
8. Landiolol for heart rate control in patients with septic shock and persistent tachycardia: a multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2021.
9. J-Land 3S Investigators. Landiolol for tachycardia in septic shock: multicenter trial results.
10. Landiolol in septic shock — no one-size-fits-all approach [commentary]. Heart Lung Circ. 2024.
11. The Washington Manual of Critical Care, 4th ed. 2025 — septic shock and adjunctive cardiovascular therapy chapters.
12. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant septic shock content.